These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34966276)

  • 1. A Systematic Review of Economic Evaluations of Active Tuberculosis Treatments.
    Byun JY; Kim HL; Lee EK; Kwon SH
    Front Pharmacol; 2021; 12():736986. PubMed ID: 34966276
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of a decentralized care model for managing multi-drug-resistant tuberculosis in low- and middle-income countries: a systematic review protocol.
    Mahapatra B; Bhattacharya P; Karuveettil V; John D; Khatoon S; Mukherjee N; Jankiram C
    JBI Evid Synth; 2024 Jan; 22(1):97-105. PubMed ID: 37779435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of economic evaluations of pharmacological treatments for active tuberculosis.
    Nagar S; Nicholls D; Dawoud D
    Front Public Health; 2024; 12():1201512. PubMed ID: 38689771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing Uncertainties Due to Limited Evidence in Economic Evaluations of Novel Anti-Tuberculosis Regimens: A Systematic Review.
    Padmasawitri TIA; Saragih SM; Frederix GW; Klungel O; Hövels AM
    Pharmacoecon Open; 2020 Jun; 4(2):223-233. PubMed ID: 31297751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
    Mpobela Agnarson A; Williams A; Kambili C; Mattson G; Metz L
    Expert Rev Anti Infect Ther; 2020 May; 18(5):475-483. PubMed ID: 32186925
    [No Abstract]   [Full Text] [Related]  

  • 7. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accurate diagnosis of latent tuberculosis in children, people who are immunocompromised or at risk from immunosuppression and recent arrivals from countries with a high incidence of tuberculosis: systematic review and economic evaluation.
    Auguste P; Tsertsvadze A; Pink J; Court R; Seedat F; Gurung T; Freeman K; Taylor-Phillips S; Walker C; Madan J; Kandala NB; Clarke A; Sutcliffe P
    Health Technol Assess; 2016 May; 20(38):1-678. PubMed ID: 27220068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic and modeling evidence for tuberculosis preventive therapy among people living with HIV: A systematic review and meta-analysis.
    Uppal A; Rahman S; Campbell JR; Oxlade O; Menzies D
    PLoS Med; 2021 Sep; 18(9):e1003712. PubMed ID: 34520463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.
    Lu X; Smare C; Kambili C; El Khoury AC; Wolfson LJ
    BMC Health Serv Res; 2017 Jan; 17(1):87. PubMed ID: 28122562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D; Dass R; Hettle R
    BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of shortened, bedaquiline-containing treatment regimens for rifampicin-resistant tuberculosis (STREAM stage 2): a within-trial analysis of a randomised controlled trial.
    Rosu L; Madan JJ; Tomeny EM; Muniyandi M; Nidoi J; Girma M; Vilc V; Bindroo P; Dhandhukiya R; Bayissa AK; Meressa D; Narendran G; Solanki R; Bhatnagar AK; Tudor E; Kirenga B; Meredith SK; Nunn AJ; Bronson G; Rusen ID; Squire SB; Worrall E;
    Lancet Glob Health; 2023 Feb; 11(2):e265-e277. PubMed ID: 36565704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testing strategies for Lynch syndrome in people with endometrial cancer: systematic reviews and economic evaluation.
    Stinton C; Jordan M; Fraser H; Auguste P; Court R; Al-Khudairy L; Madan J; Grammatopoulos D; Taylor-Phillips S
    Health Technol Assess; 2021 Jun; 25(42):1-216. PubMed ID: 34169821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
    Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
    PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review.
    Laurence YV; Griffiths UK; Vassall A
    Pharmacoeconomics; 2015 Sep; 33(9):939-55. PubMed ID: 25939501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation.
    Leaviss J; Davis S; Ren S; Hamilton J; Scope A; Booth A; Sutton A; Parry G; Buszewicz M; Moss-Morris R; White P
    Health Technol Assess; 2020 Sep; 24(46):1-490. PubMed ID: 32975190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic Evaluation of Screening Strategy for Latent Tuberculosis Infection (LTBI) in Contacts of Tuberculosis Patients: Systematic Review and Quality Assessment.
    Yoopetch P; Chitpim N; Jittikoon J; Udomsinprasert W; Thavorncharoensap M; Youngkong S; Praditsitthikorn N; Mahasirimongkol S; Chaikledkaew U
    Int J Environ Res Public Health; 2022 Oct; 19(20):. PubMed ID: 36294107
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.